AIDS-Related Lymphoma | NYU Langone Health
Doctors at Perlmutter Cancer Center provide expert care for people who have AIDS-related lymphoma, a group of cancers that begin in white blood cells.
Airway Abnormality Services for Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone offer advanced diagnostic tools and treatments for airway abnormalities in children.
Airway Center | NYU Langone Health
NYU Langone’s Airway Center provides evaluation and treatment for adults and children with upper airway problems.
Airway Center Doctors | NYU Langone Health
Find a doctor at the Airway Center at NYU Langone.
Airway Clearance for Nontuberculous Mycobacterial Infections | NYU Langone Health
NYU Langone doctors may recommend techniques to prevent mucus building up in the lungs from a nontuberculous mycobacterial infection.
Airway Clearance Techniques for Cystic Fibrosis in Children | NYU Langone Health
Experts at NYU Langone provide ongoing support and education on airway clearance techniques to treat cystic fibrosis in children.
Airway Monitoring for Cystic Fibrosis in Children | NYU Langone Health
Doctors at NYU Langone regularly monitor people with cystic fibrosis for signs of lung infections.
Airway, Breathing & Lung Conditions | NYU Langone Health
NYU Langone doctors specialize in treating infections and diseases of the lungs, including asthma, bronchitis, chronic cough, and lung cancer.
Alcohol Septal Ablation for Hypertrophic Cardiomyopathy | NYU Langone Health
NYU Langone electrophysiologists may perform alcohol septal ablation, an alternative to surgical treatment for hypertrophic cardiomyopathy.
Alexion NEPH-202 Ravulizumab trial
Chronic kidney disease (CKD) has become a worldwide public health issue due to its highincidence, poor prognosis, and substantial economic burden. When not properly diagnosed andmanaged, CKD can lead to many adverse outcomes such as end-stage renal disease (ESRD).Despite advances in immunosuppressive treatments, certain types of glomerulonephritis such aslupus nephritis (LN) and immunoglobulin A nephropathy (IgAN) continue to respond poorly totreatment, resulting over time in CKD. No disease-specific therapies are currently available,therefore effective treatments for managing LN and IgAN represent a high unmet medical need.The pathophysiology of glomerular diseases such as LN and IgAN involves a complex overlapof abnormal cellular immune response, loss of humoral immune tolerance, aberrant coagulation,and systemic inflammation. Complement dysregulation has emerged as an additional drivingfactor that interplays with these pathways in LN and IgAN. The narrow vessels and highperfusion in the kidney make this organ particularly susceptible to complement-mediated injury.Histologic evidence of complement deposition observed upon kidney biopsy of patients witheither LN or IgAN suggests a pathological role. This theory is supported by the association ofserum complement levels with disease activity and response to treatment, particularly in patientswith LN.The objectives of this study are to evaluate the safety and efficacy of ravulizumab(ULTOMIRIS®) administered by intravenous (IV) infusion compared to placebo anddemonstrate proof-of-concept of the efficacy of terminal complement inhibition in participantswith LN or IgAN.